|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1445 New York Avenue, NW, #800 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1331-12
|
||||||||
|
6. House ID# 303290000
|
TYPE OF REPORT | 8. Year | 2016 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shawn Friesen |
Date | 1/23/2017 4:55:42 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015).
Lobby members of House and Senate to write to FDA regarding the agencys draft guidance document on office-use compounding.
Support S. 2615, the Increasing Competition in Pharmaceuticals Act.
Support H.R. 4784, the Lower Drug Costs through Competition Act.
Lobby members of Congress to join the Congressional Skin Cancer Caucus.
Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, and to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription.
Lobby in support of FDAs proposed rule to restrict indoor tanning for youth under 18.
Lobby Congress on issues related to telemedicine.
Advocate for increased price transparency for drugs and tools to help lower costs.
Advocate for increased funding and reforms to Graduate Medical Education including Ensuring Childrens Access to Specialty Care Act (H.R. 1859/S. 2782).
Oppose paragraph d, Location of Care in Section 704, Enhancement of Use of Telehealth Services in Military Health System" in the Senate-passed version of S. 2943, the National Defense Authorization Act for Fiscal Year 2017.
Lobby members of Congress to support H. Res. 854 to encourage proper sun safety practices for youth under care of schools and camps.
Support legislation to study online learning collaboratives and the impact they have on the health care systems (H.R. 5395/S. 2873 The Expanding Capacity for Health Outcomes Act aka ECHO Act).
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Support H.R. 6/H.R. 34, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures.
Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative.
Advocate for medical research, education and prevention funding at the National Institutes of Health, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality under the Labor, Health and Human Services, and Education Appropriations legislation (S.3040 and H.R. 5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017).
Oppose report language calling on the Centers for Disease Control to commission the National Academy of Science to study the efficacy and health benefits of vitamin D supplements vs. Non-burning Sunshine (H.R. 5926 and S. 3040, Departments of Labor Health and Human Services and Education, and Related Agencies Appropriations Act, 2017).
Advocate regarding proposed indoor tanning regulations and report language regarding access to compounded pharmaceuticals under the Senate and House Agriculture Appropriations bills (S.2956/H.R.5054, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017).
Advocate for funding of the Peer Reviewed Cancer Research Program in the Department of Defense Appropriations Act of 2017 (S. 3000 and H.R. 5293).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocate regarding proposed regulations under Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10).
Advocate against CMS proposal regarding collection of data for all 10- and 90- day global surgery services.
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks (S. 2392 / H.R. 4227, the Medicare Advantage Bill of Rights Act of 2015).
Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015).
Lobby Congress on improvements to Health Information Technology implementation.
Lobby Congress on issues related to telemedicine and Medicare reimbursement.
Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/ H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act).
Advocate on use and availability of health care data.
Lobby in support of legislation to provide more flexibility in the Meaningful Use program (H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act).
Advocate for EHR interoperability and enhancements to the federal certification system for health information technology; advocate for provisions to restrict data blocking by Electronic Health Records vendors (S. 2141, Transparent Ratings on Usability & Security to Transform Technology Act of 2015, S.2511, Improving Health Information Technology Act and H.R. 6/H.R. 34, 21st Century Cures Act).
Advocate for improving disease management and care coordination for patients with chronic diseases (H.R. 6/H.R. 34, 21st Century Cures Act).
Support preservation of the In-Offices Ancillary Services Exemption under Stark Law regarding physician self-referral.
Advocate against H.R. 5008, Promoting Integrity in Medicare Act of 2016
Support legislation to provide more flexibility in compliance with the Sunshine Act (S.2978).
Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act).
Support S. 2978, Protecting Continuing Physician Education & Patient Care Act.
Advocate for increased graduate medical education funding.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
Advocate for legislation to enact medical liability reforms.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services.
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act).
Support legislation that would increase pre-tax savings for Flexible Spending Accounts and allow funds to be carried over from year to year in perpetuity (H.R. 1185/S. 3242, The Responsible Additions and Increases to Sustain Employee Health Benefits Act of 2015).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |